BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
+0.05 (3.50%)
Nov 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.42 - 1.51
52 week 0.38 - 1.80
Open 1.42
Vol / Avg. 7,830.00/20,549.00
Mkt cap 70.19M
P/E     -
Div/yield     -
EPS -0.06
Shares 47.43M
Beta 2.18
Inst. own     -
Nov 5, 2014
Q3 2014 BELLUS Health Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -176.90% -43.04%
Operating margin -189.52% -71.68%
EBITD margin - -145.79%
Return on average assets -14.14% -3.83%
Return on average equity -33.97% -8.92%
Employees 9 -
CDP Score - -


275 Armand-Frappier Blvd.
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links


BELLUS Health Inc. (BELLUS Health) is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. In addition, BELLUS Health is developing Shigamab, an antibody treatment for hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (sHUS). BELLUS Health�s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body, including the kidneys, heart, liver and peripheral nerves.